이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
TG Therapeutics 대차 대조표 상태
재무 상태 기준 확인 6/6
TG Therapeutics 의 총 주주 지분은 $177.6M 이고 총 부채는 $102.9M, 이는 부채 대 자기자본 비율을 58% 로 가져옵니다. 총자산과 총부채는 각각 $401.2M 및 $223.6M 입니다. TG Therapeutics 의 EBIT는 $101.8M 이며 이자보상배율은 8.2 입니다. $217.3M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
58.0%
부채 비율
US$102.92m
부채
| 이자 보상 비율 | 8.2x |
| 현금 | US$217.25m |
| 주식 | US$177.57m |
| 총 부채 | US$223.64m |
| 총 자산 | US$401.21m |
최근 재무 상태 업데이트
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06재무 상태 분석
단기부채: TGTX 의 단기 자산 ( $389.2M )이 단기 부채( $108.7M ).
장기 부채: TGTX 의 단기 자산( $389.2M )이 장기 부채( $115.0M ).
부채 대 자본 내역 및 분석
부채 수준: TGTX 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: TGTX 의 부채 대 자기자본 비율은 지난 5년간 217% 에서 58% 로 감소했습니다.
부채 범위: TGTX 의 부채는 영업 현금 흐름 ( 65.9% )에 의해 잘 충당되었습니다.
이자 보장: TGTX 의 부채에 대한 이자 지급은 EBIT( 8.2 x 적용 범위)로 잘 충당됩니다.